Epinephrine
Epinephrine is an emergency medicine used mainly for severe allergic reactions (anaphylaxis), and certain injectable products are also used to raise dangerously low blood pressure in septic shock; one inhaler is used for mild intermittent asthma symptoms.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 88 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Epinephrine (adrenaline) is the preferred first-line emergency treatment for anaphylaxis, a severe allergic reaction, tightening leaky blood vessels to hold up blood pressure and opening the airways; on the market since about 1948 and available as a generic, it also comes in injectable forms used for low blood pressure in septic shock, a life-threatening reaction to infection. The jittery, shaky feeling, pounding heartbeat, headache or nausea that follow a dose usually fade soon and are no reason to hold it back. Use it exactly as you were taught at the first sign of trouble, then call emergency services every time, since it buys time but does not replace medical care.
Clinical pearls
- Inject only into the outer thigh; an accidental dose into a finger, hand, foot or buttock means a trip to the emergency room.
- Beta blockers such as propranolol can blunt its heart and airway effects, so tell whoever prescribes it if you take one.
- Make sure family and caregivers know where it is and how to use it, since you may not manage it yourself.
- Neffy can change the lining of the nose for up to two weeks, boosting absorption of other nasal sprays.
Patient information guide A plain-language walkthrough of Epinephrine, written from its FDA label.
What Epinephrine is used for
▾
Epinephrine is used in emergencies, and specific uses depend on the product.
- Emergency treatment of Type I allergic reactions, including anaphylaxis from insect stings or bites, foods, drugs and other allergens, plus idiopathic and exercise-induced anaphylaxis (auto-injectors, Auvi-Q, Adrenalin and other injections).
- Raising blood pressure in adults with hypotension from septic shock (Adrenalin and certain other epinephrine injections).
- Neffy nasal spray: anaphylaxis in adults and children aged 4+ weighing at least 15 kg.
- Primatene Mist inhaler: temporary relief of mild symptoms of intermittent asthma.
How Epinephrine works
▾
Epinephrine stimulates alpha and beta receptors. Alpha action reduces blood vessel widening and leakiness during anaphylaxis, helping keep blood pressure up. Beta action relaxes airway muscles, easing wheezing and trouble breathing.
It also eases itching, hives and swelling, and may relieve stomach, bowel and bladder symptoms of anaphylaxis by relaxing smooth muscle.
Epinephrine dosage
▾
Dosing depends on the product and the person's weight, so follow your prescriber and label.
- Auto-injectors and vials: injected into the outer thigh, through clothing if needed; may be repeated every 5 to 10 minutes as necessary.
- Neffy: one nasal spray, with a second in the same nostril after 5 minutes if there's no improvement.
- Septic shock products: IV infusion in a medical setting, adjusted to blood pressure.
Dosing details from the FDA-approved label
From the Epinephrine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Anaphylaxis: Adults and Children 30 kg (66 lbs) or more (Adrenalin)
- 0.3 to 0.5 mg (0.3 to 0.5 mL) of undiluted Adrenalin administered intramuscularly or subcutaneously in the anterolateral aspect of the thigh, repeated every 5 to 10 minutes as necessary
- Maximum: 0.5 mg (0.5 mL) per injection
- Use a needle at least 1/2 inch long for intramuscular administration; do not inject repeatedly at the same site
- Anaphylaxis: Children less than 30 kg (66 lbs) (Adrenalin)
- 0.01 mg/kg (0.01 mL/kg) of undiluted Adrenalin administered intramuscularly or subcutaneously in the anterolateral aspect of the thigh, repeated every 5 to 10 minutes as necessary
- Maximum: 0.3 mg (0.3 mL) per injection
- Weight-based dose; hold the child's leg firmly in place during injection
- Hypotension associated with septic shock (Adrenalin, adults)
- Intravenous infusion rate of 0.05 to 2 mcg/kg/min, titrated to achieve a desired mean arterial pressure
- May be adjusted periodically, such as every 10 to 15 minutes, in increments of 0.05 to 0.2 mcg/kg/min
- Dilute 1 mL (1 mg) in 1,000 mL of 5 percent dextrose or 5 percent dextrose and sodium chloride solution to give 1 mcg per mL
- Wean incrementally after stabilization, such as by decreasing doses every 10 minutes; avoid veins of the leg in elderly patients or those with occlusive vascular disease
- Patients greater than or equal to 30 kg (approximately 66 pounds or more) (Auvi-Q)
- AUVI-Q 0.3 mg injected intramuscularly or subcutaneously into the anterolateral aspect of the thigh
- Dose strength selected by body weight
- Patients 15 to 30 kg (33 to 66 pounds) (Auvi-Q)
- AUVI-Q 0.15 mg injected intramuscularly or subcutaneously into the anterolateral aspect of the thigh
- Dose strength selected by body weight
- Patients 7.5 to 15 kg (16.5 to 33 pounds) (Auvi-Q)
- AUVI-Q 0.1 mg injected intramuscularly or subcutaneously into the anterolateral aspect of the thigh
- Dose strength selected by body weight; doses are fixed, consider other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION The recommended dosage of AUVI-Q is based on weight. ( 2.1 ) Administer AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. ( 2.2 ) Recommended Dosage Patient’s Weight Dosage 30 kg or greater AUVI-Q 0.3 mg 15 kg to less than 30 kg AUVI-Q 0.15 mg 7.5 kg to less than 15 kg AUVI-Q 0.1 mg In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of AUVI-Q may be administered with a second autoinjector starting 5 minutes after the first dose. ( 2.1 ) Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. ( 2.1 ) It is recommended that patients are prescribed and have immediate access to two AUVI-Q devices at all times. ( 2.1 ) See full prescribing information for administration instructions. ( 2.2 ) 2.1 Recommended Dosage The recommended dosage for patients who weigh 7.5 kg or greater is based on weight and the dosage is provided in Table 1 . Administer AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh. Table 1. Recommended Dosage of AUVI-Q Based on Patient’s Weight Patient’s Weight Dosage 30 kg or greater AUVI-Q 0.3 mg 15 kg to less than 30 kg AUVI-Q 0.15 mg 7.5 kg to less than 15 kg AUVI-Q 0.1 mg Since the doses of epinephrine delivered from AUVI-Q are fixed, use other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary. In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of AUVI-Q may be administered with a second autoinjector starting 5 minutes after the first dose. Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. It is recommended that patients are prescribed and have immediate access to two AUVI-Q devices at all times. 2.2 Administration Instructions Each AUVI-Q contains a single dose of epinephrine for single use. Visually inspect the epinephrine solution in the viewing window of AUVI-Q for particulate matter, cloudiness, and discoloration prior to administration.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Epinephrine side effects
▾
Side effects vary by product, and many come from epinephrine's stimulating effect.
Common side effects
- Nasal discomfort (nasal spray)
- Headache
- Runny nose
- Dizziness
- Nausea and vomiting
- Throat irritation
- Feeling jittery or shaky
- Fast or pounding heartbeat
- Feeling jittery, tremor, anxiety
- Pounding or fast heartbeat, pallor, sweating
When to get medical help
- Get emergency medical care every time you use epinephrine for anaphylaxis. It is not a substitute for medical care.
- If epinephrine is accidentally injected into a finger, hand or foot, go to the nearest emergency room right away, since blood flow to that area can be cut off.
- If injected into the buttock, it may not work well. Go to the emergency room.
- Seek care for redness, warmth, swelling or tenderness at the injection site that doesn't go away, which can signal a rare serious infection.
- Chest pain, a racing or irregular heartbeat, or a severe headache after a dose need urgent attention.
- More than two doses in a row should only be given under direct medical supervision.
Epinephrine warnings and precautions
▾
- Get emergency care after every use. Epinephrine is not a substitute for medical care.
- Do not inject into a vein, the buttock, or fingers, hands or feet.
- Rare serious infections, including gas gangrene, can occur at the injection site.
- Use with caution in heart disease, hyperthyroidism, diabetes, older adults and pregnancy, but do not withhold it in a life-threatening emergency.
- Parkinson's symptoms may temporarily worsen.
Epinephrine interactions
▾
Several medicines can change how epinephrine works.
- Digoxin-type drugs, diuretics and heart rhythm medicines: higher risk of irregular heartbeat.
- Tricyclic antidepressants, MAO inhibitors, levothyroxine, some antihistamines and entacapone-type drugs: can boost its effects.
- Beta blockers: can block its heart and airway effects.
- Alpha blockers: can block its blood pressure effects.
- Ergot alkaloids: may reverse its blood pressure-raising effect.
- Neffy: may increase absorption of other nasal products for up to 2 weeks.
Interactions listed in the FDA-approved label
From the Epinephrine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Neffy and other nasal products: Neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.
- Cardiac glycosides, diuretics, or anti-arrhythmics: Concomitant use may increase the risk of cardiac arrhythmias. Observe carefully for the development of cardiac arrhythmias.
- Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium: May potentiate the effects of epinephrine.
- Certain antihistamines (chlorpheniramine, tripelennamine, diphenhydramine): May potentiate the effects of epinephrine.
- Catechol-O-methyl transferase (COMT) inhibitors such as entacapone: May potentiate the effects of epinephrine.
- Beta-adrenergic blocking drugs, such as propranolol: Antagonize the cardiostimulating and bronchodilating effects of epinephrine.
- Alpha-adrenergic blocking drugs, such as phentolamine: Antagonize the vasoconstricting and hypertensive effects of epinephrine.
- Ergot alkaloids: May reverse the pressor effects of epinephrine.
Read the label’s full interactions text
7 DRUG INTERACTIONS Cardiac glycosides, diuretics, or anti-arrhythmics: observe for development of cardiac arrhythmias. (7.1) Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, certain antihistamines, and catechol-O-methyl transferase inhibitors: may potentiate effects of epinephrine. (7.2) Beta-adrenergic blocking drugs: antagonize cardiostimulating and bronchodilating effects of epinephrine. (7.3) Alpha-adrenergic blocking drugs: antagonize vasoconstricting and hypertensive effects of epinephrine. (7.3) Ergot alkaloids: may reverse the pressor effects of epinephrine. (7.3) 7.1 Drugs Increasing Risk of Cardiac Arrhythmias Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.3) and Adverse Reactions (6) ] . 7.2 Drugs Potentiating Effects of Epinephrine The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine, and catechol-O-methyl transferase (COMT) inhibitors such as entacapone. 7.3 Drugs Antagonizing Effects of Epinephrine The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta- adrenergic blocking drugs, such as propranolol. The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine. Ergot alkaloids may also reverse the pressor effects of epinephrine.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Epinephrine
▾
- Tell your prescriber about heart disease, high blood pressure, thyroid problems or diabetes.
- Older adults may be more sensitive to side effects.
- Pregnancy and breastfeeding: treatment of anaphylaxis should not be delayed.
- Neffy has not been established in children under 4 years or under 15 kg.
- Sulfites in some products should not prevent emergency use.
Epinephrine overdose
▾
Too much epinephrine can cause extremely high blood pressure, which may lead to bleeding in the brain, fluid in the lungs, dangerous heart rhythm problems, pale cold skin, and kidney failure. Treatment is mainly supportive. Call 911 or Poison Help at 1-800-222-1222.
What Epinephrine does in the body
▾
In studies, Neffy nasal spray raised systolic blood pressure and pulse in healthy adults, similar to epinephrine injections early on and higher through 60 minutes. The significance of these changes for treating anaphylaxis is unclear.
How your body processes Epinephrine
▾
In studies, one Neffy 2 mg spray gave blood epinephrine levels within the range of a 0.3 mg injection over 60 minutes. An auto-injector peaked fastest (about 8 minutes), versus about 30 minutes for Neffy and 45 for needle-syringe injection. Epinephrine is rapidly inactivated in the body.
How to store Epinephrine
▾
Protect from light. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) . Do not refrigerate.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Epinephrine: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Epinephrine — the kind of thing our pharmacy team would talk through with you at the counter.
What is epinephrine used for?
▾
Do I still need to go to the hospital after using it?
▾
Where do I inject an auto-injector?
▾
What side effects should I expect?
▾
Can I use it if I have heart disease or am pregnant?
▾
Does it interact with other medicines?
▾
Is Epinephrine available over the counter?
▾
When was Epinephrine first available?
▾
Who makes Epinephrine?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Epinephrine on HelloPharmacist
Epinephrine forms and strengths (how it comes)
Epinephrine is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Epinephrine inactive ingredients by manufacturer.
Injection
How this form is used
- Auvi-Q is used for emergency treatment of allergic reactions (Type I), including anaphylaxis.
- Adrenalin vials are used for anaphylaxis and, in adults, to raise blood pressure in septic shock.
- Adrenalin (epinephrine in sodium chloride) is used for low blood pressure from septic shock in adults.
- Auvi-Q is injected into the outer thigh, through clothing if needed; the strength is chosen by body weight.
- Adrenalin vials for anaphylaxis are injected into the outer thigh and may be repeated every 5 to 10 minutes as necessary.
- Adrenalin (epinephrine in sodium chloride) is given as an IV infusion into a large vein, ready to use without dilution.
Show 8 more strengths Show fewer strengths
Nasal spray
How this form is used
- Neffy is used for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children aged 4 and older who weigh at least 15 kg.
- Neffy is sprayed into the nose, and the strength depends on body weight.
- If there is no improvement after the first spray, Neffy labeling says a second spray may be given in the same nostril after 5 minutes.
- Neffy labeling recommends having two sprays available at all times.
Inhaler
How this form is used
- Primatene Mist is used for temporary relief of mild symptoms of intermittent asthma: wheezing, chest tightness and shortness of breath.
Topical solution
Epinephrine on the U.S. market: products, makers and brands
How Epinephrine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
31 companies list 110 Epinephrine product records with the FDA, mostly as injection, nasal spray, inhaler; the earliest marketing or approval year on record is 1948. Brand names on the directory include Auvi-Q, Adrenalin, Symjepi and 11 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (30) · Kit (2) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Epinephrine is used (Medicaid data)
A general measure of how commonly Epinephrine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Epinephrine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Epinephrine prescribed? Of the 1,601 medications we measure, Epinephrine ranks #158 by Medicaid prescriptions — more than 90% of them.
Utilization by Epinephrine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
NDA019430 0.3 ML epinephrine 1 MG/ML Auto-Injector Most dispensed
Summed across the 3 of 15 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1870207
NDA020800 0.3 ML epinephrine 1 MG/ML Auto-Injector
Summed across the 1 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1870230
NDA019430 0.3 ML epinephrine 0.5 MG/ML Auto-Injector
Summed across the 3 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 727316
NDA020800 0.15 ML epinephrine 1 MG/ML Auto-Injector
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1870225
NDA201739 0.3 ML epinephrine 1 MG/ML Auto-Injector
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1870205
1 ML epinephrine 1 MG/ML Injection
Summed across the 3 of 55 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1660014
epinephrine 20 MG/ML Nasal Spray
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2693442
NDA201739 0.15 ML epinephrine 1 MG/ML Auto-Injector
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1870232
NDA201739 0.1 ML epinephrine 1 MG/ML Auto-Injector
Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1991328
epinephrine 1 MG/ML Injectable Solution
Summed across the 5 of 30 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 310132
10 ML epinephrine 0.1 MG/ML Prefilled Syringe
Summed across the 1 of 21 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 727373
epinephrine 10 MG/ML Nasal Spray
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2709207
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Epinephrine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 22 of 177 listed Epinephrine NDCs with Medicaid activity.
Compare Epinephrine products
A representative set of FDA-listed product records for Epinephrine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Inhaler | ||||
| 125 mcg | Respiratory (inhalation) | Armstrong Pharmaceuticals, Inc. × 2 listings | NDA | View NDC → |
| 💊Injection | ||||
| 0.1 mg/mL | Intravenous | A-S Medication Solutions | NDA | View NDC → |
| 0.15 mg/0.3 mL | Intramuscular, Subcutaneous | A-S Medication Solutions | ANDA | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | A-S Medication Solutions | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | A-S Medication Solutions | NDA AUTHORIZED GENERIC | View NDC → |
| 1 mg/mL | Intramuscular, Intraocular, Intravenous, Subcutaneous | A-S Medication Solutions | NDA | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | Advanced Rx Pharmacy of Tennessee, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | American Regent, Inc. | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Subcutaneous | American Regent, Inc. | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 0.15 mg/0.15 mL | Subcutaneous | Amneal Pharmaceuticals of New York LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | Amneal Pharmaceuticals of New York LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Amneal Pharmaceuticals Private Limited | ANDA | View NDC → |
| 0.15 mg/0.15 mL | Subcutaneous | Asclemed USA, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular, Subcutaneous | Asclemed USA, Inc. | ANDA | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | Asclemed USA, Inc. | NDA | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | Asclemed USA, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | Asclemed Usa Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 16 mcg/mL | Intravenous | Baxter Healthcare Corporation | NDA | View NDC → |
| 64 mcg/mL | Intravenous | Baxter Healthcare Corporation | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Baxter Healthcare Corporation × 2 listings | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | BPI Labs, LLC × 3 listings | NDA | View NDC → |
| 1 mg/mL | Intravenous | BPI Labs, LLC | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intraocular, Intravenous, Subcutaneous | BPI Labs, LLC | NDA | View NDC → |
| 30 mg/30 mL | Intramuscular, Intravenous, Subcutaneous | BPI Labs, LLC | NDA | View NDC → |
| 0.15 mg/0.3 mL | Intramuscular, Subcutaneous | Bryant Ranch Prepack | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Civica, Inc. | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intraocular, Intravenous, Subcutaneous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Fresenius Kabi USA, LLC | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Gland Pharma Limited × 3 listings | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intraocular, Intravenous, Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Glenmark Pharmaceuticals Inc., Usa × 2 listings | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intraocular, Intravenous, Subcutaneous | Glenmark Pharmaceuticals Inc., Usa | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Henry Schein, Inc. | NDA | View NDC → |
| 1 mg/mL | Intravenous | Henry Schein, Inc. | NDA | View NDC → |
| 0.1 mg/0.1 mL | Intramuscular | HF Acquisition Co LLC, DBA HealthFirst | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | NDA | View NDC → |
| 0.15 mg/0.3 mL | Intramuscular | HF Acquisition Co LLC, DBA HealthFirst | NDA | View NDC → |
| 0.15 mg/0.15 mL | Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | NDA AUTHORIZED GENERIC | View NDC → |
| 0.15 mg/0.15 mL | Intramuscular | HF Acquisition Co LLC, DBA HealthFirst | NDA | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | International Medication Systems, Limited | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | International Medication Systems, Limited | ANDA | View NDC → |
| 0.1 mg/0.1 mL | Intramuscular | kaleo, Inc | NDA | View NDC → |
| 0.15 mg/0.15 mL | Intramuscular | kaleo, Inc | NDA | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | kaleo, Inc | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | Medical Purchasing Solutions, LLC × 2 listings | NDA | View NDC → |
| 0.15 mg/0.3 mL | Intramuscular | Medical Purchasing Solutions, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 0.15 mg/0.15 mL | Intramuscular | Medical Purchasing Solutions, LLC × 2 listings | NDA | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | Medical Purchasing Solutions, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | Medical Purchasing Solutions, LLC × 2 listings | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Medical Purchasing Solutions, LLC | NDA | View NDC → |
| 1 mg/mL | Intravenous | Medical Purchasing Solutions, LLC | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Medical Purchasing Solutions, LLC. | NDA | View NDC → |
| 8 mcg/mL | Intravenous | Par Health USA, LLC | NDA | View NDC → |
| 16 mcg/mL | Intravenous | Par Health USA, LLC | NDA | View NDC → |
| 20 mcg/mL | Intravenous | Par Health USA, LLC | NDA | View NDC → |
| 32 mcg/mL | Intravenous | Par Health USA, LLC | NDA | View NDC → |
| 40 mcg/mL | Intravenous | Par Health USA, LLC | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Par Health USA, LLC × 2 listings | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | ProPharma Distribution | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | ProPharma Distribution | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intraocular, Intravenous, Subcutaneous | ProPharma Distribution | NDA | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular, Subcutaneous | Redpharm Drug | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Remedyrepack Inc. | NDA | View NDC → |
| 0.15 mg/0.15 mL | Subcutaneous | Remedyrepack Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | Remedyrepack Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular, Subcutaneous | Remedyrepack Inc. | ANDA | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Remedyrepack Inc. | NDA | View NDC → |
| 1 mg/mL | Intramuscular, Intraocular, Intravenous, Subcutaneous | Remedyrepack Inc. | ANDA | View NDC → |
| 0.15 mg/0.3 mL | Intramuscular | Sina Health Inc | NDA AUTHORIZED GENERIC | View NDC → |
| 0.15 mg/0.15 mL | Subcutaneous | Sina Health Inc | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | Sina Health Inc | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | Sina Health Inc | NDA AUTHORIZED GENERIC | View NDC → |
| 1 mg/mL | Intramuscular, Intravenous, Subcutaneous | Sina Health Inc | NDA | View NDC → |
| 0.1 mg/0.1 mL | Intramuscular | Sportpharm LLC | NDA | View NDC → |
| 0.15 mg/0.15 mL | Intramuscular | Sportpharm LLC | NDA | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular, Subcutaneous | Sportpharm LLC | ANDA | View NDC → |
| 0.3 mg/0.3 mL | Subcutaneous | Sportpharm LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | Sportpharm LLC | NDA | View NDC → |
| 0.15 mg/0.3 mL | Intramuscular, Subcutaneous | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular, Subcutaneous | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 0.15 mg/0.3 mL | Intramuscular | Viatris Specialty LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 0.15 mg/0.3 mL | Intramuscular | Viatris Specialty LLC | NDA | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | Viatris Specialty LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 0.3 mg/0.3 mL | Intramuscular | Viatris Specialty LLC | NDA | View NDC → |
| 💊Nasal spray | ||||
| EPINEPHRINE 1 mg/100uL | Nasal | ARS Pharmaceuticals Operations, Inc. | NDA | View NDC → |
| EPINEPHRINE 2 mg/100uL | Nasal | ARS Pharmaceuticals Operations, Inc. | NDA | View NDC → |
| EPINEPHRINE 2 mg/100uL | Nasal | Medical Purchasing Solutions, LLC | NDA | View NDC → |
| EPINEPHRINE 1 mg/100uL | Nasal | Sportpharm LLC | NDA | View NDC → |
| EPINEPHRINE 2 mg/100uL | Nasal | Sportpharm LLC | NDA | View NDC → |
| 💊Topical solution | ||||
| 1200 mg/15 mL | Dental, Periodontal, Subgingival | Gingi-Pak a Division of the Belport | UNAPPROVED DRUG OTHER | View NDC → |
| 💊Kits | ||||
| — | Intramuscular, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | NDA | View NDC → |
Showing 110 of 110 products — FDA National Drug Code Directory. See every product, package size and price: browse all 110 Epinephrine NDCs →
Epinephrine side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Epinephrine — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Epinephrine are fatigue, headache, pain; about 64% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Epinephrine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Epinephrine FDA approval history
How Epinephrine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Epinephrine was first approved by the FDA in 1948 (Brand: XYLOCAINE W/ EPINEPHRINE · Fresenius Kabi Usa); the first generic version was approved in 1972. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Epinephrine recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 5 Epinephrine recalls since July 2021, covering 9 product listings. Three of them are still ongoing or began in the last six months and are listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Epinephrine Injection, USP, 30 mg/30 mL (1mg/mL), 30 mL-Multiple-Dose Vial, Rx Only, For Intravenous Infusion, intramuscular and Subcutaneous Use, AMERICAN REGENT INC., SHIRLEY, NY 11967. NDC 0517-30… Lots: Lots: 25128L1C0, Exp. August 31, 2026; 25280L1C0, Exp. October 31, 2026; 26108L1C0, Exp. July 31, 2027 FDA record D-0865-2026 →
- Epinephrine Injection, USP, 1mg/mL, 1 mL single-dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-696-02 (vial), NDC 63323-696-25 (carton) Lots: Batch # 6133313, 6133314, Exp Date: 06/2026; Batch # 6133315, Exp Date: 07/2026; Batch # 6133682, Exp Date: 09/2026; Batch # 6134812, 6134813, Exp Date: 04/2027. FDA record D-0581-2026 →
- EPINEPHRINE Injection, USP, 1 mg/10mL (0.1 mg/mL), Rx only, INTERNATIONAL MEDICATION SYSTEMS, LIMITED, So. EL Monte, CA 91733, An Amphastar Pharmaceutical Company, NDC 76329-3318-1 Lots: Lot Number: EA038A5, Expiration Date: 08/2026. FDA record D-0483-2026 →
- Adrenalin (epinephrine) Injection 1mg/mL, 1mL single dose vial, Rx only, Packaged By: Henry Schein, Inc., 80 Summit View Lane, Bastian, VA 24314, Original NDC 42023-159-25 Repack NDC 0404-9810-01 Lots: Original Lot # 64103, exp. date 11/24 Repackaged Lot # 39747, exp. date 01/26 FDA record D-0342-2024 →
- Adrenalin (epinephrine injection, USP) 30 mg/30 mL (1mg/mL), 30 mL multiple dose vial, Rx only, MFG: Par Pharma, NDC 42023-168-01 Lots: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that i… FDA record D-1022-2022 →
- Epinephrine Injection, USP, Single-Dose Auto-Injectors 0.15 mg, packaged in 2 count carton, Rx only, MFG: Mylan Pharma NDC 49502-101-02 Lots: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that i… FDA record D-1014-2022 →
- Epinephrine Injection, USP, Single-Dose Auto-Injectors 0.3 mg, packaged in 2 count carton, Rx only, MFG: Mylan Pharma, NDC 49502-102-02 Lots: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that i… FDA record D-1013-2022 →
- EPI-Pen Jr, 2-PAK, (epinephrine injection, USP) Single-Dose Auto-Injectors 0.15 mg, packaged in 2 count carton, Rx only, MFG: Mylan Pharma, NDC 49502-501-02 Lots: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that i… FDA record D-1012-2022 →
- EPI-PEN 2-PAK (epinephrine injection, USP), Single-Dose Auto-Injectors 0.3 mg, Rx only, Manufactured for: Mylan Specialty LP., NDC 49502-500-02 Lots: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that i… FDA record D-0993-2022 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Oct 8, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 3992 10 dose forms · 32 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 1661387In current FDA listingsClinical drug / strength (SCD) NDA019430 0.3 ML epinephrine 0.5 MG/MLRxCUI 727316NDA019430 0.3 ML epinephrine 1 MG/MLRxCUI 1870207NDA020800 0.15 ML epinephrine 1 MG/MLRxCUI 1870225NDA020800 0.3 ML epinephrine 1 MG/MLRxCUI 1870230NDA201739 0.1 ML epinephrine 1 MG/MLRxCUI 1991328NDA201739 0.15 ML epinephrine 1 MG/MLRxCUI 1870232NDA201739 0.3 ML epinephrine 1 MG/MLRxCUI 1870205 -
Dose form (SCDF) Inhalation Powder RxCUI 2108366No current FDA listingClinical drug / strength (SCD) 0.22 MGRxCUI 1546217 -
Dose form (SCDF) Inhalation Solution RxCUI 2108382No current FDA listing -
Dose form (SCDF) Injectable Solution RxCUI 372030In current FDA listings -
Dose form (SCDF) Injection RxCUI 1660013In current FDA listingsClinical drug / strength (SCD) 1 ML epinephrine 1 MG/MLRxCUI 1660014250 ML epinephrine 0.008 MG/MLRxCUI 2719206250 ML epinephrine 0.016 MG/MLRxCUI 2695029250 ML epinephrine 0.02 MG/MLRxCUI 2713737250 ML epinephrine 0.032 MG/MLRxCUI 2707356250 ML epinephrine 0.04 MG/MLRxCUI 2719203250 ML epinephrine 0.064 MG/MLRxCUI 2707568 -
Dose form (SCDF) Metered Dose Inhaler RxCUI 746206In current FDA listingsClinical drug / strength (SCD) 160 ACTUAT epinephrine 0.125 MG/ACTUATRxCUI 2109083270 ACTUAT epinephrine 0.22 MG/ACTUATRxCUI 883806 -
Dose form (SCDF) Nasal Solution RxCUI 372031In current FDA listingsClinical drug / strength (SCD) 1 MG/MLRxCUI 313967 -
Dose form (SCDF) Nasal Spray RxCUI 2693441In current FDA listings -
Dose form (SCDF) Ophthalmic Solution RxCUI 372029No current FDA listingClinical drug / strength (SCD) 0.5 MG/MLRxCUI 1067791 MG/MLRxCUI 2442842.5 MG/MLRxCUI 3101275 MG/MLRxCUI 10678010 MG/MLRxCUI 141848 -
Dose form (SCDF) Prefilled Syringe RxCUI 727310No current FDA listingClinical drug / strength (SCD) 0.3 ML epinephrine 0.5 MG/MLRxCUI 21787900.3 ML epinephrine 1 MG/MLRxCUI 19891121 ML epinephrine 1 MG/MLRxCUI 263753310 ML epinephrine 0.1 MG/MLRxCUI 727373
Look up RxCUI 3992 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Epinephrine supply and shortage status
Whether Epinephrine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Epinephrine is currently listed in shortage by the FDA (10 presentations on record).
⚠️Currently in shortage (FDA) — EpinephrineRead the full Epinephrine shortage page — affected NDCs, other makers, and what to do →
Source: openFDA, from the FDA Drug Shortages database.
💵 What Epinephrine costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Injection · Intramuscular | 0.3 mg/0.3 mL | $141.28 each | NDC details & price history |
| Injection · Intramuscular | 0.15 mg/0.3 mL | $141.88 each | NDC details & price history |
| Injection · Subcutaneous | 0.3 mg/0.3 mL | $112.00 each | NDC details & price history |
| Injection · Subcutaneous | 0.15 mg/0.15 mL | $117.97 each | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Epinephrine brand names
Epinephrine is sold under 14 brand names in the FDA directory — Auvi-Q, Adrenalin, Symjepi, Primatene Mist Inhaler and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Epinephrine: manufacturers and labelers
31 companies list Epinephrine products with the FDA. By number of product records, the largest are HF Acquisition Co LLC, DBA HealthFirst, Medical Purchasing Solutions, LLC, Par Health USA, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 7 more on the FDA NDC directory.
Epinephrine drug class (RxNorm)
Epinephrine belongs to the alpha-Adrenergic Agonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Epinephrine page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Mylan Specialty L.P. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →